#ACImmune #AlzheimersDisease #Tautargetingtherapy #Alzheimerstrial #ACI35030 #Tautargetingactiveimmunotherapy #immunotherapy #earlyAlzheimersdisease #SupraAntigentechnology #JACI35054 #polyclonalantibody #Tau #phosphorylatedTau #pTau #brainderivedTau #ePHF #ReTaintrial
zurl.co/MY6hl
zurl.co/MY6hl
AC Immune’s Tau-targeting therapy shows promise in early Alzheimer’s trial - PharmaTimes
Early-stage study reveals strong immune response and safety profile for ACI-35.030
pharmatimes.com
October 1, 2025 at 11:43 AM